MorphoSys AG buy tbackenh
Summary
This prediction ended on 09.09.10 with a price of €16.85. With a performance of 5.25%, the BUY prediction by tbackenh for MorphoSys AG closed with a slight gain. tbackenh has 50% into this predictionMorphoSys is a German biopharmaceutical company that develops innovative therapies for the treatment of cancer, autoimmune diseases, and other serious illnesses. The company specializes in developing monoclonal antibodies, which are highly specific and targeted therapies that recognize and bind to specific cancer cells or disease-causing proteins in the body. MorphoSys has a diverse pipeline of products in various stages of development, including several drugs that have shown promising results in clinical trials. The company is listed on the Frankfurt and NASDAQ stock exchanges and has a market capitalization of over $4 billion.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| MorphoSys AG | -1.476% | -1.476% | 262.181% | -16.395% |
| iShares Core DAX® | -0.922% | -1.993% | 13.399% | 16.075% |
| iShares Nasdaq 100 | 0.371% | -0.868% | 41.541% | 46.938% |
| iShares Nikkei 225® | 2.224% | -5.187% | 20.497% | 4.643% |
| iShares S&P 500 | -0.026% | -0.918% | 30.410% | 42.418% |
Comments by tbackenh for this prediction
In the thread Morphosys AG diskutieren
Morphosys AG
Die Antikörper-Sparte von Morphosys habe einen starken Start in das Jahr 2010 hingelegt, fuhr der Commerzbank-Experte fort. In diesem Geschäftsfeld könnte das Unternehmen nun ein Umsatzwachstum von 12 Prozent und einen Zuwachs beim operativen Gewinn (EBIT) von 48 Prozent erzielen, womit sich eine EBIT-Marge von 18 Prozent ergebe. Damit würde die Antikörper-Sparte seine ursprünglichen Schätzungen übertreffen.